Liquidia Corporation (LQDA) Has 50%+ Upside on Yutrepia Ruling and Buyout Potential
Buckley Capital Advisors highlighted Liquidia Corporation (NASDAQ: LQDA) in its second-quarter 2026 investor letter, citing 50%+ upside on Yutrepia ruling and buyout potential.
Intelligence analysis by Llama
Buckley Capital Advisors' second-quarter 2026 investor letter highlighted Liquidia Corporation (NASDAQ: LQDA) for its 50%+ upside on Yutrepia ruling and buyout potential. The firm's average cost for LQDA is around $9.00, and the shares trade at around $78.
Imagine you have a special medicine that can help people with a certain disease. Liquidia Corporation is a company that makes this medicine, and it's very good at it. Some people think that this medicine is so good that another company might want to buy Liquidia Corporation, which could make the stock price go up even more.
Analysis
A $60B Vote of Confidence
Liquidia Corporation (NASDAQ: LQDA) has been a significant contributor to Buckley Capital Advisors' portfolio, with a return of over 100% so far this year. The firm's average cost for LQDA is around $9.00, and the shares trade at around $78. Buckley Capital believes that there is 50%+ upside to what an acquirer would pay for the business today. The firm is waiting on Judge Andrews' decision on whether LQDA will be able to sell its Yutrepia product for PH-ILD (pulmonary hypertension associated with interstitial lung disease).
Why Cursor?
Buckley Capital has continually adjusted its delta-adjusted position size using options as a risk management tool. The firm believes that an acquirer is likely to come in shortly after the ruling. Despite the stock's appreciation, Buckley Capital still feels that there is significant upside to what an acquirer would pay for the business today.
The Road Ahead
The article highlights the potential for Liquidia Corporation (NASDAQ: LQDA) to be acquired, with Buckley Capital believing that there is 50%+ upside to what an acquirer would pay for the business today. The firm is waiting on Judge Andrews' decision on whether LQDA will be able to sell its Yutrepia product for PH-ILD (pulmonary hypertension associated with interstitial lung disease).
Key points
- Buckley Capital Advisors highlighted Liquidia Corporation (NASDAQ: LQDA) in its second-quarter 2026 investor letter.
- The firm believes that there is 50%+ upside to what an acquirer would pay for the business today.
- Buckley Capital is waiting on Judge Andrews' decision on whether LQDA will be able to sell its Yutrepia product for PH-ILD (pulmonary hypertension associated with interstitial lung disease).
If Judge Andrews rules in Liquidia Corporation's favor, an acquirer may come in shortly after the ruling, leading to a significant increase in the stock price.
If Judge Andrews rules against Liquidia Corporation, the stock price may decline, and the company's buyout potential may be reduced.
